Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hydroxyurea and HIV infection].

D Nkoghe1, L Kola, P Léonard

  • 1Service de Médecine interne, Université de Liège.

Revue Medicale De Liege
|October 3, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hereditary angioedema (HAE) in Belgium: results from a national survey.

Frontiers in allergy·2023
Same author

Clinical practice of hereditary angioedema in Belgium: opportunities for optimized care.

Acta clinica Belgica·2023
Same author

[Apexxnar®, 20-valent pneumococcal conjugate vaccine].

Revue medicale de Liege·2022
Same author

[Phage therapy, an additional strategy against multidrug-resistant bacteria].

Revue medicale de Liege·2022
Same author

[Monkeypox].

Revue medicale de Liege·2022
Same author

[Monogenic autoinflammatory diseases. An introduction on a translational mode to].

Revue medicale de Liege·2022

Hydroxyurea shows promise in treating HIV-1 by inhibiting viral replication and enhancing nucleoside activity. While effective in combination therapy for adults and children, long-term safety requires further investigation.

Area of Science:

  • Oncology
  • Virology
  • Immunology

Context:

  • Hydroxyurea, an established anticancer agent, is being explored for its role in managing HIV-1 infection.
  • Its mechanism involves inhibiting viral replication and potentiating nucleoside analog activity, specifically didanosine (ddI).
  • The drug also exhibits cytostatic effects on CD4 and CD8 lymphocytes, crucial components of the immune system affected by HIV-1.

Purpose:

  • To evaluate the efficacy and tolerability of hydroxyurea as a therapeutic agent in HIV-1 treatment.
  • To assess hydroxyurea's potential as a complementary drug in combination therapies for HIV-1.
  • To explore the feasibility of using hydroxyurea, particularly in conjunction with didanosine, in resource-limited settings.

Summary:

  • Hydroxyurea demonstrates efficacy as an adjunct therapy in both initial multi-drug regimens and salvage therapy for HIV-1 infection.

Related Experiment Videos

  • Studies suggest that a dosage of 500 mg twice daily is well-tolerated in adults, and 20 mg/kg in children.
  • While short-term tolerance appears favorable, long-term safety data for hydroxyurea in HIV-1 treatment remain limited.

    • Impact:

    • Hydroxyurea, combined with didanosine, presents a potential therapeutic option for HIV-1 management, especially in developing nations.
    • Further research into long-term tolerance is warranted to fully establish its safety profile.
    • The findings support the investigation of hydroxyurea as a cost-effective addition to HIV-1 treatment strategies.